Investment Rating - The report maintains a "Strong Buy" rating for China Feihe (06186.HK) [1][2][3] Core Views - China Feihe is expected to benefit from a rebound in newborn numbers, leading to accelerated revenue growth in the second half of 2024. The company is improving its product structure, which is expected to enhance gross margins, despite a decrease in government subsidies and an increase in tax rates affecting net profit margins. The company has increased its cash dividend to 2.72 billion yuan, with a payout ratio of 76%, resulting in a dividend yield of approximately 5% [1][2][6] Financial Performance - For 2024, China Feihe's revenue is projected to be 20.75 billion yuan, representing a year-on-year increase of 6.2%, while net profit is expected to reach 3.65 billion yuan, up 11.1% year-on-year. The second half of 2024 is anticipated to show a revenue growth of 8.7% year-on-year [1][6][7] - The company achieved a gross margin of 66.3% in 2024, an increase of 1.5 percentage points year-on-year, driven by improvements in product structure and a decrease in raw material costs [6][7][12] - The earnings per share (EPS) forecast for 2025 and 2026 is 0.44 yuan and 0.49 yuan, respectively, with a current price-to-earnings (PE) ratio of 14 times for 2025 [1][2][7] Market Position - China Feihe's market share is steadily increasing, supported by ongoing investments in consumer education and a recovery in the infant formula sector. The company organized 920,000 face-to-face events in 2024, and online sales accounted for 22.9% of total revenue [1][2][6] Valuation Metrics - The current stock price is 6.59 HKD, with a total market capitalization of 59.8 billion HKD. The company has a return on equity (ROE) of 13.2% and a debt-to-asset ratio of 24.1% [3][6][12]
中国飞鹤（06186）：产品结构改善，分红力度加大